UNITED THERAPEUTICS Corp.
- UTHR · Nasdaq
- Pharmaceutical Preparations
- Silver Spring, MD
- 1,400 employees
- CIK 0001082554
Updated from SEC filings through
Top things to know
Executives
- Martine A. Rothblatt Chairperson & CEO 4, 2026-09-30
- James Edgemond CFO AND TREASURER 4, 2026-06-23
- James C. Edgemond Chief Financial Officer and Treasurer 10-K, 2026-02-25
- United Therapeutics Michael Benkowitz , President and Chief Operating Officer of 8-K, 2026-11-04
- Michael Benkowitz PRESIDENT AND COO 4, 2026-05-14
- Paul A. Mahon EVP & GENERAL COUNSEL 4, 2026-09-18
What leadership is saying
“Our record third quarter revenue performance reflects a business operating at a very high level, driven by strong commercial momentum and focused execution across our organization”
Earnings press release (8-K Ex. 99.1), filed November 4, 2026
UNITED THERAPEUTICS Corp is a U.S. public company in pharmaceutical preparations (SIC 2834), headquartered in Silver Spring, MD. It trades as UTHR on Nasdaq. Revenue was $3.2B in the fiscal year ending December 31, 2025, +10.6% from the year before. It reported about 1,400 employees. Martine A. Rothblatt is Chairperson & CEO.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $3.2B 10-K, 2026-02-25 | $2.9B 10-K, 2026-02-25 | $2.3B 10-K, 2026-02-25 | $1.9B 10-K, 2025-02-26 | $1.7B 10-K, 2024-02-21 |
| Operating income | $1.5B 10-K, 2026-02-25 | $1.4B 10-K, 2026-02-25 | $1.2B 10-K, 2026-02-25 | $980M 10-K, 2025-02-26 | $556M 10-K, 2024-02-21 |
| SG&A | $756M 10-K, 2026-02-25 | $710M 10-K, 2026-02-25 | $477M 10-K, 2026-02-25 | $482M 10-K, 2025-02-26 | $467M 10-K, 2024-02-21 |
| Net income | $1.3B 10-K, 2026-02-25 | $1.2B 10-K, 2026-02-25 | $985M 10-K, 2026-02-25 | $727M 10-K, 2025-02-26 | $476M 10-K, 2024-02-21 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Martine A. Rothblatt | Chairperson & CEO | 4, 2026-09-30 |
| James Edgemond | CFO AND TREASURER | 4, 2026-06-23 |
| James C. Edgemond Chief Financial Officer & Treasurer at United Therapeutics | Chief Financial Officer and Treasurer | 10-K, 2026-02-25 |
| United Therapeutics | Michael Benkowitz , President and Chief Operating Officer of | 8-K, 2026-11-04 |
| Michael Benkowitz President & COO at United Therapeutics Corporation | PRESIDENT AND COO | 4, 2026-05-14 |
| Judy D. Olian | President Emerita, Quinnipiac University | 10-K, 2026-02-25 |
| Louis Sullivan | President Emeritus, Morehouse School of Medicine; Former Secretary, U.S. Department of Health and Human Services | 10-K, 2026-02-25 |
| Ray Kurzweil | Chief AI Officer and Co-Founder, Beyond Imagination | 10-K, 2026-02-25 |
| Paul A. Mahon | EVP & GENERAL COUNSEL | 4, 2026-09-18 |
| Christopher Causey | Former Consultant and Healthcare Executive | 10-K, 2026-02-25 |
| Christopher Patusky | Founding Principal, Patusky Associates, LLC | 10-K, 2026-02-25 |
| Jan Malcolm | Former Commissioner of Health, State of Minnesota | 10-K, 2026-02-25 |
| Linda Maxwell | Surgeon; Operating Partner, DCVC | 10-K, 2026-02-25 |
| Richard Giltner | Former Portfolio Manager at Lyxor Asset Management, an asset management group at Société Générale, S.A. | 10-K, 2026-02-25 |
| Tommy Thompson | Former Governor of Wisconsin; Former Secretary, U.S. Department of Health and Human Services | 10-K, 2026-02-25 |
| Victor Dzau, M.D. | member of the Board | 8-K, 2026-07-23 |
What UNITED THERAPEUTICS Corp does
Founded by our Chairperson and Chief Executive Officer, Martine Rothblatt, to find a cure for her daughter’s life-threatening rare disease, pulmonary arterial hypertension ( PAH ), United Therapeutics advances therapies for people living with serious diseases with unmet medical needs. Our mission is to transform the treatment of rare diseases and expand the availability of transplantable organs through innovative organ manufacturing technologies.
Item 1. Business, 10-K for the year ending December 31, 2025
Shares and governance
| Shares outstanding | 42.6 million (as of October 28, 2026) | 10-Q, November 4, 2026 |
|---|---|---|
| Public float | $11.2B (as of June 30, 2025) | 10-K, February 25, 2026 |
| Latest proxy statement | Meeting June 26, 2026 (filed April 29, 2026) | DEF 14A, April 29, 2026 |
| Auditor | Ernst & Young LLP (Tysons, Virginia) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| November 6, 2026 | Martine A. Rothblatt Chairperson & CEO | Sale | 9,500 | $5.4M | Form 4, November 9, 2026 |
| November 5, 2026 | Martine A. Rothblatt Chairperson & CEO | Sale | 1,960 | $1.2M | Form 4, November 6, 2026 |
| November 5, 2026 | Martine A. Rothblatt Chairperson & CEO | Sale | 7,540 | $4.3M | Form 4, November 6, 2026 |
| November 5, 2026 | Paul A. Mahon EVP & GENERAL COUNSEL | Sale | 8,300 | $5.0M | Form 4, November 5, 2026 |
| November 4, 2026 | Martine A. Rothblatt Chairperson & CEO | Sale | 1,723 | $1.1M | Form 4, November 5, 2026 |
| November 4, 2026 | Martine A. Rothblatt Chairperson & CEO | Sale | 7,777 | $4.7M | Form 4, November 5, 2026 |
| November 3, 2026 | Martine A. Rothblatt Chairperson & CEO | Sale | 9,500 | $5.7M | Form 4, November 4, 2026 |
| November 2, 2026 | Martine A. Rothblatt Chairperson & CEO | Sale | 9,500 | $5.7M | Form 4, November 3, 2026 |
Recent 8-K events
- 8-K filed 2026-11-04
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-10-22
- Item 8.01 Other events
- 8-K filed 2026-10-14
- Item 8.01 Other events
- 8-K filed 2026-09-08
- Item 1.01 Entry into a material definitive agreement
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-08-05
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-07-23
- Item 5.02 Departure or appointment of directors or officers; compensation
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-06-29
- Item 5.02 Departure or appointment of directors or officers; compensation
- Item 5.07 Submission of matters to a vote of security holders
- 8-K filed 2026-05-06
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-03-30
- Item 8.01 Other events
- 8-K filed 2026-03-09
- Item 1.01 Entry into a material definitive agreement
- Item 7.01 Regulation FD disclosure
Frequently asked questions about UNITED THERAPEUTICS Corp
- What does UNITED THERAPEUTICS Corp do?
- In its own words, from Item 1 of its 10-K: "Founded by our Chairperson and Chief Executive Officer, Martine Rothblatt, to find a cure for her daughter’s life-threatening rare disease, pulmonary arterial hypertension ( PAH ), United Therapeutics advances therapies for people living with serious diseases with unmet medical needs. Our mission is to transform the treatment of rare diseases and expand the availability of transplantable organs through innovative organ manufacturing technologies."
- What is UNITED THERAPEUTICS Corp's revenue?
- $3.2B for the fiscal year ending December 31, 2025, from its 10-K filed February 25, 2026.
- Is UNITED THERAPEUTICS Corp profitable?
- UNITED THERAPEUTICS Corp reported net income of $1.3B for the fiscal year ending December 31, 2025.
- How many employees does UNITED THERAPEUTICS Corp have?
- About 1,400 as of December 31, 2025, as stated in its annual report.
- Who is the CEO of UNITED THERAPEUTICS Corp?
- Martine A. Rothblatt, Chairperson & CEO, as named in a 4 filed September 30, 2026.
- Who is the CFO of UNITED THERAPEUTICS Corp?
- James Edgemond, CFO AND TREASURER, as named in a 4 filed June 23, 2026.
- Where is UNITED THERAPEUTICS Corp headquartered?
- Silver Spring, MD.
- What is UNITED THERAPEUTICS Corp's stock ticker?
- UTHR on Nasdaq.
- What industry is UNITED THERAPEUTICS Corp in?
- Pharmaceutical Preparations, SIC code 2834.
- What is UNITED THERAPEUTICS Corp's website?
- unither.com.
- When does UNITED THERAPEUTICS Corp report earnings next?
- February 3, 2027. Source: estimate_8k_pattern.
- Is UNITED THERAPEUTICS Corp a public company?
- Yes. UNITED THERAPEUTICS Corp files with the SEC under CIK 0001082554 and trades as UTHR.
- Who audits UNITED THERAPEUTICS Corp?
- Ernst & Young LLP, Tysons, Virginia, as named in its latest annual report (10-K).
- How many shares of UNITED THERAPEUTICS Corp are outstanding?
- 42.6 million shares as of October 28, 2026, from its 10-Q filed November 4, 2026.
- What is UNITED THERAPEUTICS Corp's public float?
- $11.2B as of June 30, 2025, as reported on the cover of its 10-K filed February 25, 2026.
- When is UNITED THERAPEUTICS Corp's annual shareholder meeting?
- June 26, 2026, per its proxy statement (DEF 14A) filed April 29, 2026.
- Have UNITED THERAPEUTICS Corp insiders traded stock recently?
- Since October 30, 2026, officers and directors reported 9 open-market sales worth about $34.7M and 0 purchases on Forms 4 and 5. The most recent: Martine A. Rothblatt (Chairperson & CEO) sold 9,500 shares on November 6, 2026.